D-Glutamine
- Generic Name
- D-Glutamine
- Brand Names
- Endari
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O3
- CAS Number
- 5959-95-5
- Unique Ingredient Identifier
- 63HB36CA2Y
- Background
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
- Indication
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older .
- Associated Conditions
- Osteoporosis, Acute Complications of Sickle Cell Disease
- Associated Therapies
- -
Therapy of Radiation Enteritis With Glutamine
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Nanjing University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT01758783
- Locations
- 🇨🇳
Department of Surgery, Nanjing General Hospital of Nanjing Command, Nanjing, Jiangsu, China
SNE1725: Can Oral Glutamine Facilitate Early Return of Gut Function
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Scarborough General Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT01750138
- Locations
- 🇬🇧
Scarborough District Hospital, Scarborough, North Yorkshire, United Kingdom
Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Medical University of Bialystok
- Target Recruit Count
- 240
- Registration Number
- NCT01704664
- Locations
- 🇵🇱
Medical University of Bialystok, Bialystok, Podlaskie, Poland
Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants
- Conditions
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 10
- Registration Number
- NCT01576003
- Locations
- 🇺🇸
C.S. Mott Children's Hosptial, Ann Arbor, Michigan, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Tulane University
- Target Recruit Count
- 106
- Registration Number
- NCT01414244
- Locations
- 🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
Effect of L-arginine and Glutamine on Preterm
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 75
- Registration Number
- NCT01263041
- Locations
- 🇪🇬
NICU of Children hospital and Nicu of obstetric and gynecology hospital, ain shams university, Cairo, Egypt
Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Hospital Universitari Son Dureta
- Target Recruit Count
- 150
- Registration Number
- NCT01250782
- Locations
- 🇪🇸
Hospital Universitario Son Dureta, Palma, Islas Baleares, Spain
Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- University of Missouri, Kansas City
- Target Recruit Count
- 5
- Registration Number
- NCT01239680
- Locations
- 🇺🇸
Univeristy of Missouri-Kansas City, Kansas City, Missouri, United States
🇺🇸Truman Medical Center-Hospital Hill, Kansas City, Missouri, United States
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
- Conditions
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT01179217
- Locations
- 🇺🇸
Howard University Hospital & Howard University, Washington, District of Columbia, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Interfaith Medical Center, Brooklyn, New York, United States
Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT01087658
- Locations
- 🇨🇦
Investigational Site Number 0001, Greenfield Park, Canada
🇨🇦Investigational Site Number 124-011, Montreal, Canada
🇨🇦Investigational Site Number 124-003, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.